$3.710
-0.049 (-1.33%)Al cierre
Noticias de ZNTL
Eventos de ZNTL
Zentalis Pharmaceuticals Launches Public Offering
Zentalis Pharmaceuticals announced the commencement of a proposed underwritten public offering of shares of its common stock and in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All of the securities to be sold in the proposed offering will be sold by the company. The company intends to use the net proceeds from the offering, together with the company's existing cash, cash equivalents and marketable securities, to fund clinical trials, preclinical studies, regulatory filings, manufacturing and the Company's companion diagnostic in support of its programs, as well as for pre-commercial activities, capital expenditures, working capital and other general corporate purposes. TD Cowen, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunners for the offering.
Zentalis CEO Reports Progress on Azenosertib Trials
"We have achieved important milestones on the continued advancement of azenosertib in our registration-intended DENALI Phase 2 and ASPENOVA Phase 3 trials for patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC), including completing the enrollment of DENALI Part 2b and aligning with the U.S. Food and Drug Administration (FDA) following a Type D meeting on our selected dose and DENALI study population to support potential accelerated approval," said Julie Eastland, Chief Executive Officer of Zentalis. "We remain as confident as ever that azenosertib has the potential to be an important oral, non-chemotherapy treatment option for the approximately 50% of PROC patients with Cyclin E1-positive tumors, who have limited options. We expect to provide the topline readout of DENALI Part 2 in 1H 2027. We continue to advance the confirmatory ASPENOVA Phase 3 trial with the goal of bringing a potential first-in-class WEE1 therapy to market for this underserved patient population globally. In addition to the lead indication, we see opportunity for expansion of azenosertib into platinum-sensitive settings of ovarian cancer and additional tumor types through combinations."
Zentalis CEO Reports Progress on Azenosertib for Ovarian Cancer Patients
"This quarter, we built momentum with achievement of key milestones advancing azenosertib in our registration-intended Phase 2 and Phase 3 trials for patients with Cyclin E1-positive platinum-resistant ovarian cancer," said Julie Eastland, Chief Executive Officer of Zentalis. "Our core focus is on bringing a convenient, oral, non-chemotherapy treatment option to approximately 50% of PROC patients who are Cyclin E1-positive and may experience poorer prognosis and limited benefit from standard-of-care therapies. Pivotal dose selection supports our regulatory strategy, positioning us to pursue accelerated approval through the DENALI Part 2 trial while simultaneously advancing ASPENOVA as our confirmatory trial-together charting a pathway to bring a potential first-in-class therapy to market for this underserved patient population. Following dose selection, we initiated pre-commercial launch preparedness activities to add commercial capabilities to the organization, scale manufacturing capacity and advance Cyclin E1 companion diagnostic market development. Beyond the lead indication, we see substantial opportunity for strategic expansion of azenosertib into platinum-sensitive or first-line maintenance settings of ovarian cancer, additional tumor types, and combination approaches."
Zentalis Presents Azenosertib Data at AACR Meeting
Zentalis announced data from two posters being presented at the 2026 American Association for Cancer Research Annual Meeting, taking place April 17-22, 2026, in San Diego, CA. The data show encouraging preclinical activity of azenosertib in triple-negative breast cancer and highlight the poor prognosis of Cyclin E1-positive ovarian cancer patients with currently available treatments in a real-world data analysis. "The preclinical data in triple-negative breast cancer being presented at AACR showed that azenosertib combinations can induce complete tumor responses in a model resistant to emerging ADC therapies, supporting the potential to broaden the impact of azenosertib beyond ovarian cancer," said Julie Eastland, CEO of Zentalis. "This includes potential development of azenosertib through differentiated combination strategies with antibody-drug conjugates and chemotherapy. As ADCs advance toward first-line use in TNBC, effective post-ADC treatment strategies represent a growing unmet need that azenosertib combinations may be uniquely positioned to fill. Our data suggest azenosertib may achieve this through multiple mechanisms - possibly resensitizing tumors to chemotherapy, enhancing the responses to ADC, and extending the duration of response - which is an exciting potential future direction for our pipeline." Preclinical evidence supports azenosertib as a therapeutic strategy in TNBC: TNBC cell lines showed higher Cyclin E1 expression and greater sensitivity to WEE1 inhibition compared to other breast cancer cell lines. Azenosertib monotherapy demonstrated meaningful antitumor activity across a diverse panel of 12 TNBC in vivo xenograft models. In a patient-derived xenograft model of TNBC with clinical resistance to sacituzumab govitecan, an approved topoisomerase 1 inhibitor ADC, azenosertib + enfortumab vedotin: Induced complete responses in 7 of 8 mice; 5 mice did not progress after treatment discontinuation; Prevented tumor progression in 8 of 8 mice for more than 52 days compared to 100% progression observed within 30 days with EV alone. Drove deep tumor regression in mice models refractory to sacituzumab govitecan or trastuzumab deruxtecan with large tumor volumes. Combinations of azenosertib with TOPO1i-payload ADCs enhanced both depth and duration of response compared to ADC monotherapy in ADC-naive models. Azenosertib + paclitaxel restored substantial sensitivity to paclitaxel in a model resistant to both paclitaxel and TOPO1i ADCs.
S&P 500 Closes Slightly Lower on Friday Amid Oil Volatility
While the S&P 500 still had its best week since November, the benchmark gauge for equities closed with a small loss of Friday after a seven-day advance. Markets ended the week in a cautious holding pattern, with momentum from earlier in the week fading.Oil remains volatile as doubts grow around the durability of the Iran ceasefire as disruptions in the Strait of Hormuz persist. Meanwhile, the CPI report showed the sharpest year-over-year price increases for consumers in nearly four years, largely driven by the recent energy shock. Even with a pause in fighting, oil flows remain constrained and supply chains are still disrupted, meaning inflation pressure doesn't immediately disappear. While the ceasefire triggered a global relief rally, investors were on edge Friday as they braced for high-stakes talks being led by Vice President JD Vance this weekend.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:CoreWeaveentered into a multi-yearMeanwhile, Anthropic is exploring designing its own AI chips,TSMCreported ain March net revenueMumbai-based Sun Pharmaceutical Industries has decided to proceed with a binding offer of $12 B for Organon,March's consumer inflation rateto last year, with the consensus expecting 3.4%.2. WALL STREET CALLS:Niketo Neutral at Piper SandlerShake Shackto Outperform at MizuhoServiceNowto Neutral at UBSCiti isin the application software group with six downgrades, including Autodeskand DocuSignIBMwith a Buy at Citi3. AROUND THE WEB:Nike'sinnovation chief Tony Bignell plans to leave the company, WSJ reportsYouTubehas raised prices for YouTube Premium and Music subscriptions, Variety reportsAppleplans to shut down its first unionized store in Maryland, Reuters reportsConocophillipswill evaluate oil prospects in Venezuela, Bloomberg reportsItaly is replacing Leonardochief Roberto Cingolani, Reuters says4. MOVERS:Commvaultrose after Reutersthe company is exploring a saleCars.comwas higher after announcing an increase to its buyback program and anZentalis Pharmaceuticalsgained after Guggenheimon the sharesFair Isaacfell after Barclayson the sharesRobloxwas lower after announcing the5. EARNINGS/GUIDANCE:WD-40reportedand reiterated its FY26 guidanceTecnoglassscut itsBeam GlobalreportedSimulations Plusreportedand cut its FY26 earnings guidanceLotus Technologyreported a year-over-yearINDEXES:The Dow fell 269.23, or 0.56%, to 47,916.57, the Nasdaq gained 80.48, or 0.35%, to 22,902.89, and the S&P 500 declined 7.77, or 0.11%, to 6,816.89.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.